Cynata Therapeutics (ASX:CYP)
Company Profile
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Cynata Therapeutics.
RELATED STOCKHEAD STORIES
Biocurious: With Mayne Pharmaceuticals under takeover offer, who’s next?
Health Check: Ahead of Chemist Warehouse merger, brokers ring bell on ‘overvalued’ Sigma shares
Health Check: Local biotech starred in 2024, but the rising tide did not lift all boats
Scott Power: The lowdown on Sonic’s $700m German excursion
Health Check: Biotech’s forgotten tortoises pick up the pace as sector emerges from two-year slump
Health Check: Pro Medicus founders cashed up for the festive season
Dr Boreham’s Crucible: This stem cell and regenerative medicine firm has four shots at the jackpot
Alive and Kicking: Watch this space on controversy-free stem-cell therapy trials, says Cynata
ASX Health Stocks: Big tick for Cynata’s stem-cell therapy
ASX Health Stocks: Imricor installs key equipment at Swiss hospital
ASX Health Winners in May: LTR Pharma leads, and why hopes are high for biotech stocks this year
From high-tech cancer fighters to AI-wielding crime busters, these are some of the most innovative firms on the ASX
Up close and personal with ASX tech and Biotech
